Teva Pharmaceutical Industries Ltd. will present its transformation and growth plans through 2030 at the J.P. Morgan Healthcare Conference. The company’s innovative brands like AUSTEDO®, AJOVY®, and UZEDY® are driving growth, with clinical pipeline assets expected to fuel future growth. Expected 2025 financial performance includes revenues of $16.8-$17.0 billion and adjusted EBITDA of $4.8-$5.0 billion. Teva aims for mid-single digit revenue growth by 2030, with net leverage below 2x. The company’s commitment to innovation and better health drives its strategic direction. For more information, visit Teva’s Investor Relations website.

Read more at GlobeNewswire: Teva to Present at the 44th Annual J.P. Morgan Healthcare